Erratum to: Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months
Crossref DOI link: https://doi.org/10.1007/s10620-017-4657-0
Published Online: 2017-06-28
Published Print: 2017-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Argüelles-Arias, F.
Guerra Veloz, M. F.
Perea Amarillo, R.
Vilches-Arenas, A.
Castro Laria, L.
Maldonado Pérez, B.
Chaaro, D.
Benítez Roldán, A.
Merino, V.
Ramírez, G.
Caunedo Álvarez, A.
Romero Gómez, M.
License valid from 2017-06-28